Skip to content

Ultrasound-Guided Thoracic Paravertebral Block Combined with Different Doses of Hydromorphone for Post-Thoracoscopic Analgesia: A Prospective Randomized Controlled Study

Ultrasound-Guided Thoracic Paravertebral Block Combined with Different Doses of Hydromorphone for Post-Thoracoscopic Analgesia: A Prospective Randomized Controlled Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124063
Enrollment
Unknown
Registered
2026-05-06
Start date
2026-05-06
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-thoracoscopic Pain

Interventions

low-dose hydrocodone group:Hydromorphone 0.05 mg/kg diluted to 100 mL with 0.9% normal saline and administered via a patient-controlled intravenous analgesia (PCIA) pump.
The medium-dose hydromorphone group:Hydromorphone 0.075 mg/kg diluted to 100 mL with 0.9% normal saline and administered via a patient-controlled intravenous analgesia (PCIA) pump.
High-dose hydrocodone group:Hydromorphone 0.10 mg/kg diluted to 100 mL with 0.9% normal saline and administered via a patient-controlled intravenous analgesia (PCIA) pump.
control group:Sufentanil 2 µg/kg diluted to 100 mL with 0.9% normal saline and administered via a patient-controlled intravenous analgesia (PCIA) pump.

Sponsors

The Second Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 40–75 years, regardless of gender; 2. American Society of Anesthesiologists (ASA) physical status I–III; 3.Scheduled to undergo unilateral video-assisted thoracoscopic surgery (VATS) lobectomy or segmentectomy under general anesthesia; 4.No significant preoperative cognitive impairment and able to understand pain assessment methods; 5. Signed informed consent before surgery.

Exclusion criteria

Exclusion criteria: 1. Allergy to local anesthetics, hydromorphone, or sufentanil; 2. Combined severe heart, liver, or kidney dysfunction; 3. Long-term use of opioids or history of drug abuse; 4. Mental illness or communication disorders; 5. Conversion from VATS to open chest during surgery; 6. TPVB puncture failure or local anesthetic extravasation; 7. Patients requiring continued mechanical ventilation or ICU admission postoperatively.

Design outcomes

Primary

MeasureTime frame
VAS (Visual Analogue Scale) scores at rest and during activity at 24 hours postoperatively;

Secondary

MeasureTime frame
Changes in VAS scores at key postoperative time points;24-hour rescue analgesic consumption;Analgesia satisfaction score (0–10);Fluctuation range of hemodynamic parameters (heart rate, mean arterial pressure) ;

Countries

China

Contacts

Public ContactSong Jie

The Second Hospital of Anhui Medical University

efy110418@fy.ahmu.edu.cn+86 135 0050 4205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026